The objective of this project is to generate rabies virus neutralizing human monoclonal antibody (mAbs), preferentially of the high affinity IgG isotype, so that a """"""""cocktail"""""""" of several neutralizing human mAbs can be prepared against multiple antigenic sites on the viral glycoprotein (GP) and ribonucleoprotein (RNP) complex. Specifically, this project aims to: (l) generate at least 15 high-affinity, virus-neutralizing human mAbs against various antigenic determinants on rabies virus using human hybridoma technology and (2) show that these mAbs protect animals against lethal rabies challenge. B cells isolated from peripheral blood (10-14 days) after booster vaccine) will be immortalized by infection with EBV, and cells producing rabies virus-specific antibody, detected in culture supernatants by ELISA, will be fused to produce mouse-human hybrids. These hybrids will be cloned, and cells producing rabies virus-specific antibody expanded. Rabies virus-specific mAbs generated in this fashion will be fully characterized in vitro for isotype, specificity, affinity, and VNA titre and in vivo for post-exposure efficacy in mice and the Syrian hamster model.
| Champion, J M; Kean, R B; Rupprecht, C E et al. (2000) The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods 235:81-90 |
